KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Interest Expenses (2019 - 2025)

Historic Interest Expenses for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $94.2 million.

  • Royalty Pharma's Interest Expenses rose 4320.19% to $94.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $307.7 million, marking a year-over-year increase of 3642.91%. This contributed to the annual value of $307.7 million for FY2025, which is 3642.91% up from last year.
  • Latest data reveals that Royalty Pharma reported Interest Expenses of $94.2 million as of Q4 2025, which was up 4320.19% from $79.6 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Interest Expenses registered a high of $94.2 million during Q4 2025, and its lowest value of $37.4 million during Q1 2021.
  • Over the past 5 years, Royalty Pharma's median Interest Expenses value was $47.0 million (recorded in 2021), while the average stood at $53.7 million.
  • In the last 5 years, Royalty Pharma's Interest Expenses tumbled by 3017.51% in 2021 and then surged by 4754.25% in 2025.
  • Royalty Pharma's Interest Expenses (Quarter) stood at $47.0 million in 2021, then fell by 0.04% to $47.0 million in 2022, then rose by 0.64% to $47.3 million in 2023, then surged by 39.16% to $65.8 million in 2024, then soared by 43.2% to $94.2 million in 2025.
  • Its last three reported values are $94.2 million in Q4 2025, $79.6 million for Q3 2025, and $68.7 million during Q2 2025.